Table 4 Clinical studies investigating toxicity and outcome of SBRT with FFF beams
From: Safety of high-dose-rate stereotactic body radiotherapy
Current study | Wang 2014 [ 31 ] | Prendergast 2013 [ 29 ] | Alongi 2013 [ 26 ] | Navarria 2013 [ 28 ] | Alongi 2012 [ 27 ] | Scorsetti 2011 [ 30 ] | |
|---|---|---|---|---|---|---|---|
Patients (Lesions) | 84 (100) | 20 (22) | 64 | 40 | 46 | 25 (28) | 67 (70) |
Tumor | Various (mostly lung) | HCC | Lung | Prostate | NSCLC Stage I | Abdominal/pelvic LN | Various (mostly lung) |
RT schedule | 21 – 66 Gy (3–15 fx) | 40 - 75 Gy (3–10 fx) | 30 – 60 Gy (3–5 fx) | 35 Gy (5 fx) | 48 Gy (4 fx) | 45 Gy (6 fx) | 32 – 75 Gy (3–6 fx) |
Median follow-up (range) | 11 months (3–46) | 7 months (3–13) | 12 months (3–25) | 11 months (5–16) | 16 months (2–24) | 6 months (2–19) | NA7 |
Acute toxicity 1 ≥ G3 | 0% | 5%3,6 | 2%4 | 0% | 4%4,6 | 0% | 3%4 |
Late toxicity 1 ≥ G3 | 1%2 | 12%4,5 | 0% | 0% | - | ||
Local control | 1-y-LC: 94% | Actuarial-LC: 95% | NA8 | NA8 | 1-y-LC: 100% | Actuarial-LC: 100% | Actuarial-LC: 89% |